Efficacy and Safety of Ophthalmic Steroids in the Management of Polypoidal Choroidal Vasculopathy: A Systematic Review
Open Access
- 1 March 2025
- journal article
- review article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 915-931
Abstract
Purpose: This review aims to clarify the role of ophthalmic steroids in polypoidal choroidal vasculopathy (PCV) treatment. Methods: A systematic literature search was performed using Scopus, PubMed, MEDLINE, Cochrane, ProQuest, and manual searches. The primary outcome was changes in best-corrected visual acuity. The secondary outcomes were anatomical changes and incidence of adverse events. Results: Of the 100 articles identified, 9 studies were included: six treatment-naive studies, two anti-VEGF resistant studies, and one involving hemorrhagic retinal detachment. Triamcinolone acetonide was administered in seven studies, and dexamethasone in two. Altogether, 194 eyes received ophthalmic steroids in the form of intravitreal solution and slow-released implant. Overall, eight out of nine studies revealed visual acuity improvement from baseline to final follow-up, although only two studies reported significant results (0.33 ± 0.29 logMAR and 0.66 ± 0.28 logMAR) to final follow-up (0.16 ± 0.27 logMAR and 0.36 ± 0.31 logMAR). Adverse events were documented in six studies, with cataracts (6/96) and ocular hypertension (10/96) being the most common. Polyp regression and pigment epithelial detachment rates demonstrated a decline ranging from 50% to 100%. The maximum reduction observed in the central foveal thickness and central retinal thickness was − 131.4 μm and − 261.7 μm, respectively. Conclusion: Ophthalmic steroids may serve as an effective adjunctive treatment for PCV patients, irrespective of anti-VEGF resistance or hemorrhagic involvement, and may be considered as a potential monotherapy in resource-limited settings, with minimal side effects.Keywords
This publication has 44 references indexed in Scilit:
- Dexamethasone implant improves anatomic response to anti-VEGF therapy in treatment-resistant polypoidal choroidal vasculopathyInternational Ophthalmology, 2021
- Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal VasculopathyJAMA Ophthalmology, 2020
- Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET StudyJAMA Ophthalmology, 2018
- Proteolytic Degradation and Inflammation Play Critical Roles in Polypoidal Choroidal VasculopathyThe American Journal of Pathology, 2017
- Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2017
- Photodynamic Therapy With or Without Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy: Two Years of Follow-UpAmerican Journal of Ophthalmology, 2012
- Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2012
- A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein OcclusionArchives of Ophthalmology (1950), 2009
- A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Standard Care to Treat Vision Loss Associated With Macular Edema Secondary to Branch Retinal Vein OcclusionArchives of Ophthalmology (1950), 2009
- Polypoidal Choroidal VasculopathyArchives of Ophthalmology (1950), 2003